• Home
  • NEW DAY MEDICINE
  • 5 (37) 2021
  • 10 -5 (37) 2021 — Rakhmanova U. U. — FEATURES OF THE RESPONSE OF THE CELLULAR LINK OF THE IMMUNE SYSTEM IN PATIENTS WITH THALASSEMIA TO THE USE OF CHELATION THERAPY

10 -5 (37) 2021 — Rakhmanova U. U. — FEATURES OF THE RESPONSE OF THE CELLULAR LINK OF THE IMMUNE SYSTEM IN PATIENTS WITH THALASSEMIA TO THE USE OF CHELATION THERAPY

FEATURES OF THE RESPONSE OF THE CELLULAR LINK OF THE IMMUNE SYSTEM IN PATIENTS WITH THALASSEMIA TO THE USE OF CHELATION THERAPY 

Rakhmanova U. U. Urgency branch of Tashkent Medical Academy

Resume

Patients with thalassemia often die during the newborn period, some live to school and adolescence. Thalassemia is a hereditary genetic disease that is associated with pathological changes in the hemoglobin gene. The aim of the study was to study the features of the cellular link of immunity in patients with beta-thalassemia receiving chelation therapy, to assess the relationship of CD3+ -, CD4+ -, CD8+ -, CD16+ – with iron overload.A significant difference was revealed in all indicators of CD 3+-, CD4+-, CD8+-, CD16+- depending on the indicators of ferritin. It was found that with an increase in ferritin of 2000 ng / mg and above, there is a decrease in CD 3+ – 1.4 times, CD 4+ – 1.3 times, and an increase in CD 8+ – 1.5 times, CD 16+ – 1.2 times.

Key words: hemolysis, hemosiderosis, immunity,cellular link of immunity, chelation  therapy,  ferritin.

First page

38

Last page

40

For citation: Rakhmanova U. U. FEATURES OF THE RESPONSE OF THE CELLULAR LINK OF THE IMMUNE SYSTEM IN PATIENTS WITH THALASSEMIA TO THE USE OF CHELATION THERAPY //New Day in Medicine 5(37)2021 38-40 https://cutt.ly/3TEMwHR

LIST OF REFERENCES:

  1. Asadov CH. D., Ragimov A.A. Immunologicheskiye narusheniya pri b-talassemii (obzor literatury) // Sluzhba  krovi. 2011. №1. –S.56-59
  2. Bakhovadinov B.B., Kucher M.A., Tret’yakova A.YU. Puti sovershenstvovaniya profilaktiki posttransfuzionnykh gemoliticheskikh oslozhneniy. //Uchenyye zapiski SPbGMU im. akad. I.P. Pavlova. – 2015. – T.22. – №4. – S.90-95.
  3. de Dreuzy E., Bhukhai K., Leboulch P., Payen E. Current and future alternative therapies for beta-thalassemia major //Biom. J., 39 (1) (2016 Feb), pp. 24-38
  4. Daher A.M., Al-Momen H., Jasim S.K. Deferasirox in thalassemia: a comparative study between an innovator drug and its copy among a sample of   Iraqi   patients. Ther Adv Drug Saf. 2019 Oct 9;10
  5. El-Beshlawy A., El-Ghamrawy M. Recent trends in treatment of thalassemia.// Blood Cells Mol Dis. 2019 May; 76:53-58.
  6. Galanello R., Origa R. Beta-thalassemia.  //Orphanet J Rare Dis. 2010; 5:

file

download